First Manhattan CO Biocryst Pharmaceuticals Inc Transaction History

First Manhattan CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $7.89 Million - $11.8 Million	-993,832 Reduced 53.18%	874,840 $7.3 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $667,800 - $903,120	63,600 Added 3.52%	1,868,672 $21.5 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $14.2 Million - $32.3 Million	1,805,072 New	1,805,072 $19.1 Million

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.